David Darling

Title: David Darling: Innovator in Urothelial Carcinoma Detection

Introduction

David Darling is a notable inventor based in Dunedin, New Zealand. He has made significant contributions to the field of medical diagnostics, particularly in the detection of urothelial carcinoma. His innovative approach combines genetic and phenotypic biomarkers to improve patient outcomes.

Latest Patents

David Darling holds a patent for "Methods for detecting genetic and phenotypic biomarkers of urothelial carcinoma and treatment thereof." This patent introduces new methods for identifying patients with hematuria who are at low risk of having urothelial cancer (UC). The invention features the G+P INDEX, which integrates selected phenotypic variables with levels of genotypic expression. This metric assesses factors such as age, sex, smoking history, and frequency of hematuria alongside genetic markers like MDK, CDC2, HOXA13, IGFBP5, and optionally IL8Rb. The G+P INDEX categorizes patients into three risk groups: High Risk, Risk, and Low Risk of UC. This innovative approach can save substantial time, effort, and funds by avoiding unnecessary medical diagnostic procedures for patients identified as Low Risk.

Career Highlights

David Darling is associated with Pacific Edge Limited, a company focused on developing innovative cancer diagnostics. His work has been instrumental in advancing the understanding and detection of urothelial carcinoma, contributing to improved patient care and management.

Collaborations

David has collaborated with notable colleagues, including James Miller Suttie and Mark Dalphin. These partnerships have enhanced the research and development of diagnostic methods in the field of oncology.

Conclusion

David Darling's contributions to the detection of urothelial carcinoma through innovative methods highlight his role as a leading inventor in medical diagnostics. His work not only advances scientific understanding but also improves patient care and resource management in healthcare.